Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other Non-Current Liabilities (2022 - 2024)

Oramed Pharmaceuticals' Other Non-Current Liabilities history spans 3 years, with the latest figure at $60000.0 for Q3 2024.

  • For Q3 2024, Other Non-Current Liabilities fell 1.64% year-over-year to $60000.0; the TTM value through Sep 2024 reached $60000.0, down 1.64%, while the annual FY2023 figure was $11000.0, 81.97% down from the prior year.
  • Other Non-Current Liabilities reached $60000.0 in Q3 2024 per ORMP's latest filing, roughly flat from $60000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $99000.0 in Q1 2022 to a low of $11000.0 in Q4 2023.
  • Average Other Non-Current Liabilities over 3 years is $60090.9, with a median of $61000.0 recorded in 2022.
  • The largest YoY upside for Other Non-Current Liabilities was 10.0% in 2023 against a maximum downside of 81.97% in 2023.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $61000.0 in 2022, then tumbled by 81.97% to $11000.0 in 2023, then surged by 445.45% to $60000.0 in 2024.
  • Per Business Quant, the three most recent readings for ORMP's Other Non-Current Liabilities are $60000.0 (Q3 2024), $60000.0 (Q2 2024), and $63000.0 (Q1 2024).